Should we proceed with further evaluation for cardiac amyloidosis?

Should You Proceed with Further Evaluation for Cardiac Amyloidosis?

Yes, proceed immediately with further evaluation if the patient has heart failure symptoms plus ANY of the following red flags: unexplained LV wall thickness >12mm, age >60 with low-flow low-gradient aortic stenosis and preserved EF, bilateral carpal tunnel syndrome, peripheral neuropathy/dysautonomia, or established AL/ATTR amyloidosis in another organ. 1

When to Suspect Cardiac Amyloidosis

The 2020 Canadian Cardiovascular Society/Canadian Heart Failure Society guidelines provide clear triggers for diagnostic workup 1:

Proceed with evaluation when heart failure presents with ≥1 of:

• Unexplained increased LV wall thickness (>12mm without another cause like hypertension)
• Age >60 years with low-flow low-gradient aortic stenosis and LVEF >40%
• Bilateral carpal tunnel syndrome (often precedes cardiac symptoms by years)
• Unexplained peripheral sensorimotor neuropathy and/or dysautonomia
• Established AL or ATTR amyloidosis in non-cardiac organs (e.g., renal AL causing nephrotic syndrome)

A critical pitfall: the need to reduce or discontinue antihypertensive medications (especially beta-blockers or ACE inhibitors) in previously hypertensive patients should immediately raise suspicion 1.

Initial Diagnostic Algorithm

Step 1: Basic Workup 1

• 12-lead ECG
• Troponin and BNP/NT-proBNP
• Mandatory screening for AL amyloidosis: serum and urine protein electrophoresis with immunofixation PLUS serum free light chain (sFLC) assay

Critical caveat: Serum and urine protein electrophoresis alone are insufficient—small monoclonal proteins may be missed. Both immunofixation and sFLC assay are necessary 1.

Step 2: Advanced Cardiac Imaging 1

Echocardiography with longitudinal LV strain measurement OR cardiac MRI with late gadolinium enhancement and T1 mapping should be performed in ALL suspected cases (Strong Recommendation) 1.

Key echocardiographic findings:

• LV wall thickness >12mm with small/normal chamber size
• Reduced global longitudinal strain with apical sparing (base-to-apex gradient) - this is relatively specific and differentiates amyloidosis from other causes of LV hypertrophy 1
• Grade ≥2 diastolic dysfunction
• Biventricular wall thickening, valve thickening, small pericardial effusion

Key CMR findings:

• Diffuse transmural or subendocardial late gadolinium enhancement
• Global extracellular volume >0.40
• Abnormal gadolinium kinetics (myocardial nulling before blood pool)
• Elevated native T1 mapping

Subtype Differentiation

If monoclonal protein is ABSENT and imaging suggests amyloidosis:

• Proceed with 99mTc-PYP/DPD/HMDP bone scintigraphy to diagnose ATTR cardiac amyloidosis non-invasively 1, 2
• Nuclear scintigraphy showing cardiac uptake in the absence of monoclonal protein confirms ATTR without need for biopsy
• Then perform TTR genetic testing to distinguish hereditary (hATTR) from wild-type (wtATTR)

If monoclonal protein IS PRESENT or sFLC ratio is abnormal:

• Urgent hematology referral 1
• Tissue biopsy required (endomyocardial biopsy, bone marrow, or involved organ) with Congo red staining
• Mass spectrometry or immunohistochemistry for amyloid typing
• Do NOT rely on nuclear scintigraphy alone—AL amyloidosis can also show radiotracer uptake 1

Important pitfall: Monoclonal gammopathy of undetermined significance (MGUS) is common in older patients with wtATTR. When MGUS coexists with positive bone scintigraphy, you cannot assume ATTR—biopsy with amyloid typing is mandatory 1, 2.

When Endomyocardial Biopsy is Necessary

Perform endomyocardial biopsy when: 1, 3

• Noninvasive evaluation is equivocal or negative despite high clinical suspicion
• Monoclonal protein detected with positive nuclear scan (to exclude AL)
• Fat pad or bone marrow biopsy is negative but suspicion remains high (these have only 15-45% sensitivity for ATTR)

Endomyocardial biopsy with Congo red staining has ~100% specificity and sensitivity for detecting amyloid deposits and remains the gold standard in equivocal cases 3.

Why Early Diagnosis Matters for Outcomes

Cardiac involvement is the strongest predictor of mortality in systemic amyloidosis 4. Disease-modifying therapies are now available that improve survival:

• For ATTR: Tafamidis reduces mortality (HR 0.70) and vutrisiran reduces cardiovascular events (HR 0.72) 5
• For AL: Chemotherapy regimens can halt disease progression when started early

The prognosis depends heavily on disease stage at diagnosis—advanced cardiac amyloidosis carries poor outcomes even with treatment 5, 6. Delays in diagnosis are common because symptoms are non-specific and the disease is often misattributed to hypertensive heart disease or hypertrophic cardiomyopathy, particularly in younger patients 7.

Bottom line: The threshold for proceeding with evaluation should be low. Missing the diagnosis has devastating consequences, while the diagnostic workup (starting with blood tests and echocardiography) is straightforward and readily available 4, 8.